Aberdeen Group Trims Stake in Guardant Health

Institutional investor reduces ownership in cancer diagnostics company

Apr. 9, 2026 at 7:21am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking financial machinery and instruments in muted industrial tones, conceptually representing the institutional forces shaping the cancer diagnostics market.Aberdeen Group's reduction in Guardant Health shares reflects broader investor uncertainty around the cancer diagnostics company's long-term outlook.Redwood City Today

Aberdeen Group plc, an institutional investor, has reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 35.1% in the fourth quarter, according to a recent SEC filing. The firm now owns 75,124 shares of the company's stock, down from 115,701 shares previously.

Why it matters

Guardant Health is a leading provider of liquid biopsy tests for cancer detection and monitoring. The company's stock has seen significant volatility as investors weigh its growth potential against competition in the diagnostics market. Aberdeen Group's move to trim its position could signal broader investor sentiment around the stock.

The details

According to the filing, Aberdeen Group sold 40,577 shares of Guardant Health during the fourth quarter. The firm now owns a 0.06% stake in the company, valued at $7.67 million as of the end of the quarter. Several other institutional investors have also adjusted their Guardant Health positions in recent months, both increasing and decreasing their ownership.

  • Aberdeen Group filed the 13F report disclosing the stake reduction on April 9, 2026.
  • The trades occurred during the fourth quarter of 2025.

The players

Aberdeen Group plc

A global investment management firm that provides asset management services to institutional and retail clients worldwide.

Guardant Health, Inc.

A precision oncology company that develops non-invasive liquid biopsy tests to detect and monitor cancer.

Got photos? Submit your photos here. ›

The takeaway

Aberdeen Group's decision to trim its Guardant Health stake could signal broader investor uncertainty around the company's long-term prospects, despite its leadership in the liquid biopsy space. This move highlights the competitive dynamics and volatility in the cancer diagnostics industry.